Thiết kế chất ức chế dựa trên mảnh cho protease chính của SARS-CoV2

Carlos WG, Dela Cruz CS, Cao B, Pasnick S, Jamil S (2020) Novel Wuhan (2019-nCoV) coronavirus. Am J Respir Crit Care Med P7–P8 Drosten C, Günther S, Preiser W, Van Der Werf S, Brodt HR, Becker S, Doerr HW (2003) Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 348(20):1967–1976 Zaki AM, Van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA (2012) Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 367(19):1814–1820 Kaye HS, Marsh HB, Dowdle WR (1971) Seroepidemiologic survey of coronavirus (strain OC 43) related infections in a children’s population. Am J Epidemiol 94(1):43–49 Hendley JO, Fishburne HB, Gwaltney JM Jr (1972) Coronavirus infections in working adults: eight-year study with 229 E and OC 43. Am Rev Respir Dis 105(5):805–811 McIntosh K, Dees JH, Becker WB, Kapikian AZ, Chanock RM (1967) Recovery in tracheal organ cultures of novel viruses from patients with respiratory disease. Proc Natl Acad Sci USA 57(4):933 Woo PC, Lau SK, Chu CM, Chan KH, Tsoi HW, Huang Y, Yuen KY (2005) Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia. J Virol 79(2):884–895 Van Der Hoek L, Pyrc K, Jebbink MF, Vermeulen-Oost W, Berkhout RJ, Wolthers KC, Berkhout B (2004) Identification of a new human coronavirus. Nat Med 10(4):368–373 Fouchier RA, Hartwig NG, Bestebroer TM, Niemeyer B, De Jong JC, Simon JH, Osterhaus AD (2004) A previously undescribed coronavirus associated with respiratory disease in humans. Proc Natl Acad Sci 101(16):6212–6216 Li G, Fan Y, Lai Y, Han T, Li Z, Zhou P, Zhang Q (2020) Coronavirus infections and immune responses. J Med Virol 92(4):424–432 Zhang L, Lin D, Sun X, Curth U, Drosten C, Sauerhering L, Hilgenfeld R (2020) Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors. Science 368(6489):409–412 Gorbalenya AE, Baker SC, Baric R, Groot RJD, Drosten C, Gulyaeva AA, Ziebuhr J (2020) Severe acute respiratory syndrome-related coronavirus: the species and its viruses–a statement of the Coronavirus Study Group Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, White KM, Tummino TA (2020) A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature 1–13 Li YC, Bai WZ, Hashikawa T (2020) The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. J Med Virol 92(6):552–555 Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, Zhou Y (2020) Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis 94:91–95 Mlcochova P, Kemp SA, Dhar MS, Papa G, Meng B, Ferreira IA, Gupta RK (2021) SARS-CoV-2 B. 1.617. 2 Delta variant replication and immune evasion. Nature 599(7883):114–119 Karim SSA, Karim QA (2021) Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic. Lancet 398(10317):2126–2128 Ton AT, Gentile F, Hsing M, Ban F, Cherkasov A (2020) Rapid identification of potential inhibitors of SARS‐CoV‐2 main protease by deep docking of 1.3 billion compounds. Mol Inf Borgio JF, Alsuwat HS, Al Otaibi WM, Ibrahim AM, Almandil NB, Al Asoom LI, AbdulAzeez S (2020) State-of-the-art tools unveil potent drug targets amongst clinically approved drugs to inhibit helicase in SARS-CoV-2. Arch Med Sci 16(3):508 Beck BR, Shin B, Choi Y, Park S, Kang K (2020) Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model. Comput Struct Biotechnol J Ullrich S, Nitsche C (2020) The SARS-CoV-2 main protease as drug target. Bioorg Med Chem Lett 127377 Jin Z, Du X, Xu Y, Deng Y, Liu M, Zhao Y, Yang H (2020) Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature 582(7811):289–293 Nimgampalle M, Devanathan V, Saxena A (2020) Screening of chloroquine, hydroxychloroquine and its derivatives for their binding affinity to multiple SARS-CoV-2 protein drug targets. J Biomol Struct Dyn 1–13 Cherrak SA, Merzouk H, Mokhtari-Soulimane N (2020) Potential bioactive glycosylated flavonoids as SARS-CoV-2 main protease inhibitors: a molecular docking and simulation studies. PLoS ONE 15(10):e0240653 Singh R, Gautam A, Chandel S, Ghosh A, Dey D, Roy S, Ghosh D (2020) Protease inhibitory effect of natural polyphenolic compounds on SARS-CoV-2: an in silico study. Molecules 25(20):4604 Khan SA, Zia K, Ashraf S, Uddin R, Ul-Haq Z (2020) Identification of chymotrypsin-like protease inhibitors of SARS-CoV-2 via integrated computational approach. J Biomol Struct Dyn 1–10 Shaffer L (2020) 15 drugs being tested to treat COVID-19 and how they would work. Nat Med Kumar N, Awasthi A, Kumari A, Sood D, Jain P, Singh T, Chandra R (2022) Antitussive noscapine and antiviral drug conjugates as arsenal against COVID-19: a comprehensive chemoinformatics analysis. J Biomol Struct Dyn 40(1):101–116 Dai W, Zhang B, Jiang XM, Su H, Li J, Zhao Y, Liu H (2020) Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease. Science 368(6497):1331–1335 Jin Z, Zhao Y, Sun Y, Zhang B, Wang H, Wu Y, Rao Z (2020) Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur. Nat Struct Mol Biol 27(6):529–532 Durgam L, Guruprasad L (2022) Computational studies on the design of NCI natural products as inhibitors to SARS-CoV-2 main protease. J Biomol Struct Dyn (Accepted) Kumar A, Voet A, Zhang KYJ (2012) Fragment based drug design: from experimental to computational approaches. Curr Med Chem 19(30):5128–5147 Congreve M, Carr R, Murray C, Jhoti H (2003) A‘rule of three’for fragment-based lead discovery? Drug Discovery Today 8(19):876–877 Jhoti H, Williams G, Rees DC, Murray CW (2013) The‘rule of three’for fragment-based drug discovery: where are we now? Nat Rev Drug Discovery 12(8):644–644 Brown N (2015) In silico medicinal chemistry: computational methods to support drug design. Royal Society of Chemistry de Souza Neto LR, Moreira-Filho JT, Neves BJ, Maidana RLBR, Guimarães ACR, Furnham N, Silva FP Jr (2020) In silico strategies to support fragment-to-lead optimization in drug discovery. Front Chem 8:93 Murray CW, Newell DR, Angibaud P (2019) A successful collaboration between academia, biotech and pharma led to discovery of erdafitinib, a selective FGFR inhibitor recently approved by the FDA. MedChemComm 10(9):1509–1511 Bollag G, Tsai J, Zhang J, Zhang C, Ibrahim P, Nolop K, Hirth P (2012) Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat Rev Drug Discovery 11(11):873–886 Lamb YN (2019) Pexidartinib: first approval. Drugs 79(16):1805–1812 Erlanson DA, de Esch IJ, Jahnke W, Johnson CN, Mortenson PN (2020) Fragment-to-lead medicinal chemistry publications in 2018. J Med Chem 63(9):4430–4444 Baker M (2013) Fragment-based lead discovery grows up: with multiple drug candidates in the clinic that originated from fragment-based lead discovery, the approach of starting small has become big. Nat Rev Drug Discovery 12(1):5–8 Denis JDS, Hall RJ, Murray CW, Heightman TD, Rees DC (2021) Fragment-based drug discovery: opportunities for organic synthesis. RSC Medicinal Chemistry 12(3):321–329 Su HX, Yao S, Zhao WF, Li MJ, Liu J, Shang WJ, Xu YC (2020) Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian preparations and bioactive ingredients. Acta Pharmacol Sin 41(9):1167–1177 Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE (2004) UCSF Chimera-a visualization system for exploratory research and analysis. J Comput Chem 25(13):1605–1612 Hao GF, Jiang W, Ye YN, Wu FX, Zhu XL, Guo FB, Yang GF (2016) ACFIS: a web server for fragment-based drug discovery. Nucleic Acids Res 44(W1):W550–W556 Yang JF, Wang F, Jiang W, Zhou GY, Li CZ, Zhu XL, Yang GF (2018) PADFrag: a database built for the exploration of bioactive fragment space for drug discovery. J Chem Inf Model 58(9):1725–1730 Kolb P, Caflisch A (2006) Automatic and efficient decomposition of two-dimensional structures of small molecules for fragment-based high-throughput docking. J Med Chem 49:7384–7392 Dallakyan S, Olson AJ (2015) Small-molecule library screening by docking with PyRx. In Chem Biol (pp. 243–250). Humana Press, New York, NY Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, Olson AJ (2009) AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem 30(16):2785–2791 Daina A, Michielin O, Zoete V (2017) SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep 7(1):1–13 Hess B, Kutzner C, Van Der Spoel D, Lindahl E (2008) GROMACS 4: algorithms for highly efficient, load-balanced, and scalable molecular simulation. J Chem Theory Comput 4(3):435–447 Hornak V, Abel R, Okur A, Strockbine B, Roitberg A, Simmerling C (2006) Comparison of multiple amber force fields and development of improved protein backbone parameters. Proteins 65(3):712–725 Wang J, Wang W, Kollman PA, Case DA (2006) Automatic atom type and bond type perception in molecular mechanical calculations. J Mol Graph Model 25(2):247–260 Sousa da Silva AW, Vranken WF (2012) ACPYPE-antechamber python parser interface. BMC Res Notes 5(1):1–8 Berendsen HJ, Postma JP, van Gunsteren WF, Hermans J (1981) Interaction models for water in relation to protein hydration. In Intermolecular forces (pp. 331–342). Springer, Dordrecht Bussi G, Donadio D, Parrinello M (2007) Canonical sampling through velocity rescaling. J Chem Phys 126(1):014101 Parrinello M, Rahman A (1981) Polymorphic transitions in single crystals: a new molecular dynamics method. J Appl Phys 52(12):7182–7190 Darden T, York D, Pedersen L (1993) Particle mesh Ewald: an N⋅ log (N) method for Ewald sums in large systems. J Chem Phys 98(12):10089–10092 Hess B, Bekker H, Berendsen HJ, Fraaije JG (1997) LINCS: a linear constraint solver for molecular simulations. J Comput Chem 18(12):1463–1472 Kumari R, Kumar R, Open Source Drug Discovery Consortium & Lynn A (2014) g_mmpbsa A GROMACS tool for high-throughput MM-PBSA calculations. J Chem Inf Model 54(7):1951–1962 Aqvist J, Marelius J (2001) The linear interaction energy method for predicting ligand binding free energies. Comb Chem High Throughput Screening 4(8):613–626 Kollman PA, Massova I, Reyes C, Kuhn B, Huo S, Chong L, Cheatham TE (2000) Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. Acc Chem Res 33(12):889–897 Gilson MK, Honig B (1988) Calculation of the total electrostatic energy of a macromolecular system: solvation energies, binding energies, and conformational analysis. Proteins 4(1):7–18 Almlöf M, Brandsdal BO, Åqvist J (2004) Binding affinity prediction with different force fields: examination of the linear interaction energy method. J Comput Chem 25(10):1242–1254 Carlson HA, Jorgensen WL (1995) An extended linear response method for determining free energies of hydration. J Phys Chem 99(26):10667–10673 Loida PJ (1994) Molecular specificity of substrate recognition and activation in cytochrome P-450 (CAM). Doctoral dissertation, University of Illinois at Urbana-Champaign Bakan A, Meireles LM, Bahar I (2011) ProDy: protein dynamics inferred from theory and experiments. Bioinformatics 27(11):1575–1577 Bakan A, Bahar I (2009) The intrinsic dynamics of enzymes plays a dominant role in determining the structural changes induced upon inhibitor binding. Proc Natl Acad Sci 106(34):14349–14354 Yang L, Song G, Carriquiry A, Jernigan RL (2008) Close correspondence between the motions from principal component analysis of multiple HIV-1 protease structures and elastic network modes. Structure 16(2):321–330 Eyal E, Yang LW, Bahar I (2006) Anisotropic network model: systematic evaluation and a new web interface. Bioinformatics 22(21):2619–2627 Maisuradze GG, Liwo A, Scheraga HA (2009) Principal component analysis for protein folding dynamics. J Mol Biol 385(1):312–329 Ross C, Nizami B, Glenister M, Sheik Amamuddy O, Atilgan AR, Atilgan C, Tastan Bishop Ö (2018) MODE-TASK: large-scale protein motion tools. Bioinformatics 34(21):3759–3763 Ertl P, Rohde B, Selzer P (2000) Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. J Med Chem 43(20):3714–3717 Daina A, Michielin O, Zoete V (2014) iLOGP: a simple, robust, and efficient description of n-octanol/water partition coefficient for drug design using the GB/SA approach. J Chem Inf Model 54(12):3284–3301 Potts RO, Guy RH (1992) Predicting skin permeability. Pharm Res 9(5):663–669